

…at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES



[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

STRATEGIC PRIORITIES

1	2	3
Advance platform in new indications and therapeutic areas	**Commercialize Idefirix® in first markets and indications**	**Build organizational capablitlies and expand technology platform**

ANTICIPATED FUTURE MILESTONES



Updated 2022-04-21

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	145 (~2/3 in R&D)
Key Executives	Peter Nicklin, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q3 2022)

Market Cap	USD ~240m	
52 Week Range	SEK 47-120	
Avg. Daily Turnover	vol. 282k shares	
Shares Outstanding	45m	
Top 5 Shareholders	Redmile Group	11.8%
	AP4	5.0%
	NXT2B	4.8%
	Invesco	4.4%
	Avanza	4.2%

STOCK CHART (1Y)

KEY FINANCIALS

SEKm	2019	2020	2021
Revenue	3m	6m	34m
R&D cost	-193m	-227m	-231m
Net loss	-360m	-421m	-548m
Cash & Short investment	601m	1,378m	889m
Operating Cash Flow	-335m	-290m	-481m
Employees	74	87	133

** Unaudited*

CALENDAR

Oct 20, 2022	Redeye After Work presentation, Gothenburg
Oct 21, 2022	Redeye Lunch presentation, Stockholm
Oct 26, 2022	Økonomisk Ugebrev Life Science Conference
Oct 27, 2022	HCA Capital Expert call
Nov 10-11, 2022	Bryan, Garnier & Co NDRS Paris & London
Nov 22, 2022	Bryan Garnier KOL Expert call
Nov 23, 2022	SEB Healthcare Seminar 2022, Stockholm
Nov 24, 2022	Redeye Life Science Day, Stockholm
Dec 1, 2022	Erik Penser Banks Temadag - Health Care
Dec 2, 2022	Geneva Corporate Access Midcap Event, Geneva
Dec 15, 2022	DNB Nordic Healthcare Conference, Oslo
Jan 9, 2023	JPM Week, San Francisco

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corp. Comms.
M: +46(0)768-198 326
katja.margell@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATING PATHOGENIC IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



OUR BUSINESS MODEL

Growth engine	Value chain		Commercialization		
Leveraging our proprietary antibody cleaving enzyme technology	We are controlling the full value chain		Build-up of franchises	Indications and therapies	Multiple income streams
F(ab')2 Fc	Drug discovery	Drug development	Own commercial infrastructure	Transplantation	Revenue / sales
	Supply Operations	Distribution		Autoimmune diseases	Upfront payments
			Partnership strategy	Gene therapy	Milestone payments
				Oncology	Royalties

Evolution into a fully integrated biopharmaceutical company

Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
*) In the US a new study has commenced targeting a BLA filing by H1 2024

HANSA BIOPHARMA